PMID- 19398874
OWN - NLM
STAT- MEDLINE
DCOM- 20090526
LR  - 20220316
IS  - 1349-3329 (Electronic)
IS  - 0040-8727 (Linking)
VI  - 218
IP  - 1
DP  - 2009 May
TI  - Plasma urotensin II as a marker for severity of rheumatic valve disease.
PG  - 57-62
AB  - In developing countries, rheumatic valve disease (RVD) is still prevalent. 
      Management of RVD depends on symptomatology, physical examination and 
      echocardiographic evaluation, all of which, however, might be inadequate. 
      Reliable biomarkers to establish severity of RVD and predict complications would 
      be highly beneficial. Urotensin II is regarded as a cardiovascular 
      autacoid/hormone, and its role in cardiovascular diseases is emerging. We 
      hypothesized urotensin II might have pathophysiological roles in RVD. We 
      investigated 71 patients with RVD (mean age 40 +/- 12 years, 17 female patients) 
      and 25 normal subjects (mean age 40 +/- 7 years, 8 female patients). We assessed 
      their New York Heart Association (NYHA) functional class, RVD severity and 
      pulmonary artery pressure (PAP), and measured plasma urotensin II levels. Mitral 
      regurgitation (r = 0.226, p = 0.02), tricuspid regurgitation (r = 0.238, p = 
      0.02), PAP (r = 0.320, p = 0.01), and NYHA class (r = 0.213, p = 0.03) correlated 
      positively with urotensin II levels. There was positive correlation between 
      urotensin II levels and severity of mitral regurgitation (r = 0.248, p = 0.01) 
      and tricuspid regurgitation (r = 0.326, p = 0.001). In linear regression 
      analysis, only PAP was predictive of urotensin II (beta = 0.3; p = 0.02). In 
      conclusion, this is the first study showing that plasma urotensin II is elevated 
      in chronic RVD, associated with severe mitral and tricuspid valve regurgitation. 
      Furthermore, urotensin II level is correlated with NYHA functional class, and the 
      increase in PAP is predictive of plasma urotensin II.
FAU - Ozer, Orhan
AU  - Ozer O
AD  - Gaziantep University, School of Medicine, Department of Cardiology, Gaziantep, 
      Turkey.
FAU - Davutoglu, Vedat
AU  - Davutoglu V
FAU - Ercan, Suleyman
AU  - Ercan S
FAU - Akcay, Murat
AU  - Akcay M
FAU - Sari, Ibrahim
AU  - Sari I
FAU - Sucu, Murat
AU  - Sucu M
FAU - Celik, Ahmet
AU  - Celik A
FAU - Aksoy, Nur
AU  - Aksoy N
FAU - Cicek, Hulya
AU  - Cicek H
FAU - Al, Behcet
AU  - Al B
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - Japan
TA  - Tohoku J Exp Med
JT  - The Tohoku journal of experimental medicine
JID - 0417355
RN  - 0 (Biomarkers)
RN  - 0 (Urotensins)
RN  - 9047-55-6 (urotensin II)
SB  - IM
MH  - Adult
MH  - Biomarkers/*blood
MH  - Blood Pressure/physiology
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Mitral Valve Insufficiency/blood/pathology/physiopathology
MH  - Rheumatic Heart Disease/*blood/pathology/physiopathology
MH  - Tricuspid Valve Insufficiency/blood/pathology/physiopathology
MH  - Urotensins/*blood
EDAT- 2009/04/29 09:00
MHDA- 2009/05/27 09:00
CRDT- 2009/04/29 09:00
PHST- 2009/04/29 09:00 [entrez]
PHST- 2009/04/29 09:00 [pubmed]
PHST- 2009/05/27 09:00 [medline]
AID - JST.JSTAGE/tjem/218.57 [pii]
AID - 10.1620/tjem.218.57 [doi]
PST - ppublish
SO  - Tohoku J Exp Med. 2009 May;218(1):57-62. doi: 10.1620/tjem.218.57.